Skip to Content

Astellas Receives an Action Letter from FDA for NDA of FK506 MR in the U.S.

TOKYO, Jan. 23, 2007-Astellas Pharma Inc. today announced that its US subsidiary, Astellas Pharma US, Inc. received an action letter from the US Food and Drug Administration for the New Drug Application regarding its once daily immunosuppressant FK506 Modified Release formulation on Jan. 19, 2007.

For the full release, see attachment.

Posted: January 2007